{
    "nct_id": "NCT06180954",
    "official_title": "A Phase I, Open-label, Two-part Study of the Absorption, Metabolism, Excretion, and the Absolute Bioavailability of [14C]-LOXO-305 in Healthy Male Subjects",
    "inclusion_criteria": "* Must have Body mass index (BMI) within the range of 18.5 to 32.0 kilograms per square meter (kg/mÂ²), inclusive\n* Male participants in good health, determined by no clinically significant findings from medical history, 12-lead Electrocardiogram (ECG), vital sign measurements, or clinical laboratory evaluations as assessed by the investigator\n* Participants who are capable of fathering a child must agree to use contraception from the time of the dose administration through 6 months after the last dose of LOXO-305 administration\n* History of a minimum of 1 bowel movement per day\nHealthy volunteers allowed\nMust be MALE\nMust have minimum age of 18 Years\nMust have maximum age of 55 Years",
    "exclusion_criteria": "* History or presence of any diseases or conditions of clinical significance by the Investigator (or designee) and/or Sponsor\n* Positive serologic test for hepatitis B surface antigen (HBsAg), hepatitis B virus (HBV) core antibody, hepatitis C virus (HCV) antibody, or human immunodeficiency virus (HIV) antibody at Screening\n* Positive polymerase chain reaction (PCR) test for COVID-19 at Screening or Check-in (Day -1)\n* Known ongoing alcohol and/or drug abuse within 2 years prior to Screening\n* History of significant hypersensitivity, intolerance, or allergy to any drug compound, food, or other substance, unless approved by the Investigator (or designee)\n* Part 1 only: Participation in a radiolabeled drug study where exposures are known to the Investigator (or designee) within the previous 4 months prior to Check-in (Day -1) or participation in a radiolabeled drug study where exposures are not known to the Investigator (or designee) within the previous 6 months prior to Check-in (Day -1).\n* Part 2 only: Participation in any other radiolabeled investigational study drug trial within 12 months prior to Check-in (Day -1). Any previous radiolabeled study drug must have been received more than 12 months prior to Check-in (Day -1).",
    "miscellaneous_criteria": ""
}